Q2FY23 Financial Summary and Strategic Highlights
Accelerating changes to create value and further leverage enterprise scale
Adding value to our operating units, enabling stronger performance vs smaller competitors
Operations
and supply
chain
Patient safety
and quality
Portfolio
management
•
•
•
Consolidating global operations to
realize economies of scale, drive lower
costs through reduced inventory and
obsolete products & materials, and
improve quality with Strategic Supplier
base
Investing in automation, digitalization,
and Industry 4.0
Supply management team negotiates
contracts across OUs to secure attractive
terms and manage through supply chain.
issues
10
Investor Meetings | November 2022
Accelerating plans to enhance patient
safety and quality as a competitive
advantage where we 'play big'
Design, Reliability, and Manufacturability
(DRM) being implemented enterprise-
wide to deliver outcomes that are better
for patient safety; on track to cover 100%
of products
Elevating quality as part of enhanced
M&A due diligence & integration process
Quality goals aligned with leadership
incentives
Newly created Capital Allocation
Committee driving more decisive capital
allocation; includes CEO, CFO, Portfolio
Presidents and Head of Strategy
9 acquisitions since FY21 with total
combined consideration of >$3.3B;
Announced NewCo with RCS + DaVita
and separation of PM & RI businesses
Deeply committed to driving.
shareholder value
Medtronic
Engineering the extraordinary
intersect
ENT
AFFERA
DavitaⓇ
Kidney Care
ACUTUS
MEDICAL
Left Heart Access
Portfolio
RIST
NEUROVASCULAR
ADDEDS MATTERS
CATHWORKS
MedtronicView entire presentation